On 15 – 18 September 2024 the staff of the Laboratory of Monitored Therapy, Clinical Pharmacokinetics and Toxicology (Agnieszka Czajkowska, M.Sc. and Arkadiusz Kocur, Ph.D.) participated in the 22nd International Meeting of the Society for Monitored Therapy, Clinical Pharmacokinetics and Toxicology, held in Banff, Canada.
Our representatives presented 11 reports on the use of alternative sampling techniques for diagnostic testing in the paediatric population.
Two poster reports were particularly noteworthy:
Therapeutic drug monitoring of selected antibiotics using the volumetric absorptive-microsampling device (VAMS) in the paediatric population with sepsis: bioanalytical and pharmacokinetic aspects of ANTISEPSIS study
and
Therapeutic drug monitoring of selected antiviral and antifungal agents using the volumetric absorptive-microsampling device (VAMS) in the pediatric population with sepsis: bioanalytical aspects of ANTISEPSIS study
The posters presented the first results of the analytical part of the AntiSepsis project (Impact of targeted dosing based on a clinical pharmacokinetics model of antimicrobial drugs on clinical outcome and quality of life in children and neonates – safety, efficacy and cost-effectiveness analysis) funded by the Medical Research Agency.
The AntiSepsis project is carried out in the Department of Anaesthesiology and Intensive Care and the Laboratory of Monitored Therapy, Clinical Pharmacokinetics and Toxicology. The main objective of the project is to study the pharmacokinetics of antimicrobial drugs used in septic infections. The increasing resistance of bacteria to antibiotics, the problem of establishing dosing algorithms for these drugs in the paediatric population and their potential toxicity have justified the need to address this topic.
Most importantly, the project will be conducted using a microsampling technique that allows a significant reduction in the amount of blood drawn for testing. The research conducted in the project will result in the determination of drugs in a single drop of blood. The optimisation and validation of analytical methods for the determination of antimicrobial drugs in blood microsamples is currently being advanced. Inclusion of the first patient in the study is planned for March 2025. Implementation of the study will last until 2030.
The Principal Investigator: Małgorzata Mikaszewska-Sokolewicz, M.D., Ph.D., Head of the Department of Anaesthesiology and Intensive Care. The lead co-investigators are: Agnieszka Czajkowska, M.D., M.Sc., and Arkadiusz Kocur M.D., Ph. o zdr., heading the analytical-diagnostic and pharmacokinetic parts of the AntiSepsis project, respectively.